<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171365</url>
  </required_header>
  <id_info>
    <org_study_id>09115</org_study_id>
    <nct_id>NCT01171365</nct_id>
  </id_info>
  <brief_title>Small Particle Steroids in Refractory Asthma</brief_title>
  <acronym>SPIRA</acronym>
  <official_title>Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an inhaled steroid with a small particle
      size can be an additional treatment option in patients with refractory eosinophilic asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have identified a group of patients with refractory asthma who have ongoing eosinophilic
      airway inflammation despite high dose inhaled corticosteroids.

      Traditional inhaled steroids have a relatively proximal airway distribution which may lead to
      inadequate treatment of the distal airways.

      We aim to demonstrate that a steroid inhaler with a smaller particle size which targets the
      distal airways can be a useful additional treatment option in this group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in sputum eosinophil count over the trial period</measure>
    <time_frame>0 weeks (start), 8 weeks (finish)</time_frame>
    <description>Sputum will be processed for a differential cell count, with the primary outcome the difference in sputum eosinophil count between active and placebo groups at 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in alveolar nitric oxide level over the trial period</measure>
    <time_frame>0 weeks (start), 4 weeks, 8 weeks (finish)</time_frame>
    <description>alveolar nitric oxide has been shown to correlate with eosinophil count on BAL samples. Measured by measuring exhaled nitric oxide at multiple flow rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bronchial nitric oxide level</measure>
    <time_frame>0 weeks (start), 4 weeks, 8 weeks (finish)</time_frame>
    <description>Measured by single flow exhaled nitric oxide at 50 ml/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prebronchodilator FEV1</measure>
    <time_frame>0 weeks (start), 4 weeks, 8 weeks (finish)</time_frame>
    <description>Prebronchodilator FEV1 and FVC will be recorded with a Vitalograph Wedge Bellows spirometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Juniper Asthma Control Questionnaire (ACQ) score</measure>
    <time_frame>0 weeks (start), 4 weeks, 8 weeks (finish)</time_frame>
    <description>UK English Version 2001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Juniper Asthma Quality of Life Questionnaire (AQLQ) score</measure>
    <time_frame>0 weeks (start), 4 weeks, 8 weeks (finish)</time_frame>
    <description>Self-administered United Kingdom Version 1994</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of oral steroid over the trial period</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>Dose and duration of any additional oral corticosteroid will be documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events as a measure of safety and tolerability</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>Adverse events will be recorded throughout the trial period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ciclesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciclesonide 320 microgrammes twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 inhalations twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
    <description>Inhaled ciclesonide 320mcg twice daily</description>
    <arm_group_label>Ciclesonide</arm_group_label>
    <other_name>Alvesco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo inhaler two inhalations twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80

          -  ACQ &gt;1.5 or a requirement for oral steroids twice a year or more

          -  High dose inhaled steroid (&gt;1000mcg BDP or equivalent)

          -  Treatment with or unsuccessful trial of:

               -  long-acting beta agonist

               -  leukotriene antagonist

          -  Sputum eosinophil count &gt;3% despite high dose inhaled steroid or &gt;2% with serum
             eosinophils &gt;0.4x10exp9/l

          -  Clinical response to 2 weeks of oral prednisolone: (any one)

               -  reduction in ACQ by 0.5 or more

               -  increase in FEV1 by 200ml

               -  normalisation of exhaled nitric oxide or reduction of &gt;25ppb

        Exclusion Criteria:

          -  Current smoker, or ex-smoker for &lt;12 months

          -  Current treatment with an extrafine steroid inhaler

          -  Respiratory infection within the last 4 weeks

          -  Pregnancy or lactation

          -  Poor compliance with usual asthma medication

          -  Clinical diagnosis of significant bronchiectasis

          -  Use of a medication which may interact with ciclesonide:

               -  ketoconazole or itraconazole

               -  ritonavir, nelfinavir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Harrison</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Pavord</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ciclesonide</keyword>
  <keyword>Asthma</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pulmonary Eosinophilia</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

